August 25, 2021
As the project partner, BLA Regulatory congratulates ImmuneOnco on receiving US FDA approval of IMM2902 project IND
As the project partner, BLA Regulatory congratulates ImmuneOnco on receiving US FDA approval of IMM2902 project IND Gaithersburg, MD (25 August 2021) – BLA Regulatory, LLC, a full-service biopharma regulatory consultancy, announced that as the project partner, BLA Regulatory congratulates ImmuneOnco on receiving US FDA approval of IMM2902 project IND and initiating clinical investigation for […]
As the project partner, BLA Regulatory congratulates ImmuneOnco on receiving US FDA approval of IMM2902 project IND
As the project partner, BLA Regulatory congratulates ImmuneOnco on receiving US FDA approval of IMM2902 project IND Gaithersburg, MD (25...
As a partner of Chiauranib/CS2164 project, BLA Regulatory congratulates Chipscreen on receiving US FDA IND approval
As a partner of Chiauranib/CS2164 project, BLA Regulatory congratulates Chipscreen on receiving US FDA IND approval Gaithersburg, MD (03 May...
As a partner of CD4B bi-antibody project, BLA Regulatory congratulates I-Mab on receiving US FDA IND approval
As a partner of CD4B bi-antibody project, BLA Regulatory congratulates I-Mab on receiving US FDA IND approval Gaithersburg, MD (03...